- Joined
- Jan 19, 2014
- Messages
- 4,508
- Reaction score
- 21,012
Dorothy Atkins@doratki
13m
Wade points to the different Excel spreadsheets and their revenue estimates and tries to get Grossman to concede his financial model was done independently. He refuses to concede the point, and says he added data to Theranos' projections and it was based on assumptions.
Dorothy Atkins@doratki
8m
Grossman says his hedge firm's financial projections were just "a sanity check" to see if their estimates were realistic, and "this was a secondary analysis we did to see how far we could go with Walgreens and to see if [Theranos] needed to go with other partners."
Dorothy Atkins@doratki
14m
Wade shows an email from Grossman's colleague saying there's a risk the FDA could issue a cease and desist letter to Theranos "anytime bc their tests are not cleared. The FDA has not done this so Theranos is correct that such an aggressive scenario is unlikely in the near future"
Dorothy Atkins@doratki
12m
The email goes on saying CLIA does not guarantee that the FDA will not go after Theranos, and "we also have to assume that there is a possibility that they will never be able to get certain tests approved by the FDA and they will remain venous blood draw tests."
Dorothy Atkins@doratki
10m
Holmes' counsel is trying to get Grossman to concede that he the email shows he knew Theranos was using venous blood draws and that there was a risk it always would. Grossman is trying to downplay the email and says regulatory issues are "just part of this industry."
Dorothy Atkins@doratki
1m
In another Jan '14 email, Grossman's colleague said he had a due diligence call with a scientist who develops lab tests and said Theranos would need FDA approval to put its devices in Walgreens. "There's a 10-20% chance that the implementation gets derailed by the FDA," he adds.
Dorothy Atkins@doratki
24m
In an interesting twist, Holmes' counsel shows hedge fund manager Brian Grossman an analysis that he prepared on Theranos, which he showed to investors. The attorney asks if Grossman got Theranos' approval to use the Theranos logo. He says no, but he didn't think he needed to.
Dorothy Atkins@doratki
20m
Holmes' counsel points to a "business outlook" page and notes that it doesn't mention the accuracy concerns expressed that the hedge fund's analyst expressed. Grossman says: "That was not a risk that we thought was a major risk at this point of the investment.”
Dorothy Atkins@doratki
14m
Holmes' counsel points to a page in the analysis that projects Theranos to have a $20.3 billion valuation by 2020. Grossman says he "wasn’t part of this meeting," but acknowledges the stat is in the presentation.
Dorothy Atkins@doratki
9m
We're taking a 30 minute break. It seems unlikely that we'll be getting to another witness today. 0_0
Dorothy Atkins@doratki
7m
The judge says Grossman's direct exam took 1hr and 30 mins and his cross has "exceeded 6 hrs." He says his estimate that this witness won't be done until Friday seems to be coming to fruition, which will "wreak havoc" on the trial schedule, "but that’s entirely in your hands."
13m
Wade points to the different Excel spreadsheets and their revenue estimates and tries to get Grossman to concede his financial model was done independently. He refuses to concede the point, and says he added data to Theranos' projections and it was based on assumptions.
Dorothy Atkins@doratki
8m
Grossman says his hedge firm's financial projections were just "a sanity check" to see if their estimates were realistic, and "this was a secondary analysis we did to see how far we could go with Walgreens and to see if [Theranos] needed to go with other partners."
Dorothy Atkins@doratki
14m
Wade shows an email from Grossman's colleague saying there's a risk the FDA could issue a cease and desist letter to Theranos "anytime bc their tests are not cleared. The FDA has not done this so Theranos is correct that such an aggressive scenario is unlikely in the near future"
Dorothy Atkins@doratki
12m
The email goes on saying CLIA does not guarantee that the FDA will not go after Theranos, and "we also have to assume that there is a possibility that they will never be able to get certain tests approved by the FDA and they will remain venous blood draw tests."
Dorothy Atkins@doratki
10m
Holmes' counsel is trying to get Grossman to concede that he the email shows he knew Theranos was using venous blood draws and that there was a risk it always would. Grossman is trying to downplay the email and says regulatory issues are "just part of this industry."
Dorothy Atkins@doratki
1m
In another Jan '14 email, Grossman's colleague said he had a due diligence call with a scientist who develops lab tests and said Theranos would need FDA approval to put its devices in Walgreens. "There's a 10-20% chance that the implementation gets derailed by the FDA," he adds.
Dorothy Atkins@doratki
24m
In an interesting twist, Holmes' counsel shows hedge fund manager Brian Grossman an analysis that he prepared on Theranos, which he showed to investors. The attorney asks if Grossman got Theranos' approval to use the Theranos logo. He says no, but he didn't think he needed to.
Dorothy Atkins@doratki
20m
Holmes' counsel points to a "business outlook" page and notes that it doesn't mention the accuracy concerns expressed that the hedge fund's analyst expressed. Grossman says: "That was not a risk that we thought was a major risk at this point of the investment.”
Dorothy Atkins@doratki
14m
Holmes' counsel points to a page in the analysis that projects Theranos to have a $20.3 billion valuation by 2020. Grossman says he "wasn’t part of this meeting," but acknowledges the stat is in the presentation.
Dorothy Atkins@doratki
9m
We're taking a 30 minute break. It seems unlikely that we'll be getting to another witness today. 0_0
Dorothy Atkins@doratki
7m
The judge says Grossman's direct exam took 1hr and 30 mins and his cross has "exceeded 6 hrs." He says his estimate that this witness won't be done until Friday seems to be coming to fruition, which will "wreak havoc" on the trial schedule, "but that’s entirely in your hands."